| Literature DB >> 35730029 |
E L Antunes1, B M Costa2, R C Sochodolak1, L M Vargas2,3, N M Okuno2,3.
Abstract
The purpose of this study was to verify the influence of physical activity level on the length of hospital stay in older men recovered from COVID-19. In total, 126 older men diagnosed with COVID-19 were admitted to the hospital between September and December 2020. Among them, 70 survived, of which 39 older men were included in the study. Within 30 days after discharge, patients answered the International Physical Activity Questionnaire to measure their physical activity level through phone contact, with questions corresponding to the week before symptom onset. Clinical and laboratorial data from admission, days between onset of symptoms and admission, length of stay, computed tomography abnormalities, and the need for the intensive care unit were collected. The groups (active × sedentary) were compared using the Student t test or Mann-Whitney test for quantitative data and chi-square test was used for categorical data. There is no difference between the groups in characteristics of admission (p > 0.05), except by potassium level. Active older men had a shorter length of stay (6.50 ± 3.46 vs 11.48 ± 7.63 days; p = 0.03), disease duration (15.71 ± 4.84 vs 21.09 ± 7.69 days; p = 0.02), and lower frequency of lung damage when compared to their sedentary counterparts. In conclusion, being physically active prior to infection can attenuate length of hospital stay in older men with COVID-19.Entities:
Keywords: Aging; Coronavirus; Exercise; Hospitalization; Questionnaire
Year: 2022 PMID: 35730029 PMCID: PMC9187887 DOI: 10.1007/s11332-022-00948-7
Source DB: PubMed Journal: Sport Sci Health ISSN: 1824-7490
Fig. 1Flowchart of study design
Characteristics of participants classified as physically active and sedentary
| Clinical characteristics | Active ( | Sedentary ( | |
|---|---|---|---|
| Age (y) | 67.36 ± 5.90 | 66.48 ± 5.33 | 0.52 |
| Weight (kg) | 82.14 ± 9.73 | 79.40 ± 12.30 | 0.48 |
| Height (m) | 1.69 ± 0.08 | 1.70 ± 0.07 | 0.69 |
| BMI (kg.m−2) | 28.71 ± 3.06 | 27.40 ± 4.05 | 0.16 |
| HR (bpm) | 75.86 ± 12.60 | 85.27 ± 14.24 | 0.05 |
| RR (bpm) | 19.85 ± 2.12 | 23.42 ± 7.70 | 0.27 |
| SBP (mmHg) | 132.00 ± 18.60 | 129.27 ± 23.18 | 0.47 |
| DBP (mmHg) | 81.00 ± 10.16 | 84.41 ± 12.69 | 0.51 |
| Body temperature (ºC) | 36.28 ± 0.53 | 36.44 ± 0.63 | 0.52 |
| Comorbidities | |||
| 0 (%) | 4 (28.57) | 11 (44.00) | 0.18 |
| 1–2 (%) | 10 (71.63) | 11 (44.00) | |
| 3+ (%) | 0 (0.00) | 3 (12.00) | |
| Most common comorbidities | |||
| Hypertension (%) | 7 (50.00) | 10 (40.00) | 0.55 |
| Diabetes (%) | 5 (37.70) | 6 (24.00) | 0.46 |
| Oxygen therapy admission | |||
| Room air (%) | 4 (28.57) | 6 (24.00) | 0.64 |
| Nasal cannula (%) | 5 (35.71) | 5 (20.00) | |
| Non-rebreather mask (%) | 4 (28.57) | 11 (44.00) | |
| Invasive ventilation (%) | 1 (7.14) | 3 (12.00) | |
| Laboratorial exams | |||
| SaO2 (%) | 93.54 ± 3.30 | 94.49 ± 4.15 | 0.09 |
| pH | 7.41 ± 0.05 | 7.43 ± 0.06 | 0.44 |
| pO2 (mmHg) | 69.55 ± 10.47 | 74.31 ± 17.56 | 0.44 |
| pCO2 (mmHg) | 34.09 ± 4.89 | 33.45 ± 4.35 | 0.63 |
| HCO3 (mEq/L) | 21.73 ± 2.79 | 22.02 ± 2.57 | 0.83 |
| C-reactive protein (mg/L) | 15.08 ± 11.18 | 15.49 ± 10.45 | 0.92 |
| | 2.18 ± 2.71 | 2.25 ± 2.80 | 0.68 |
| Creatinine (mg/dL) | 1.01 ± 0.29 | 1.32 ± 1.24 | 0.44 |
| Urea (mg/dL) | 57.36 ± 22.27 | 61.64 ± 42.81 | 0.78 |
| Potassium (mEq/L) | 4.50 ± 0.20 | 4.30 ± 0.56 | 0.04* |
| Sodium (mEq/L) | 135.93 ± 2.84 | 136.84 ± 3.94 | 0.45 |
| Hemoglobin (g/dL) | 13.89 ± 1.72 | 13.59 ± 2.08 | 0.65 |
| Leukocytes (1000/µl) | 8.15 ± 3.49 | 8.83 ± 3.34 | 0.63 |
| Platelets (1000/µl) | 249.85 ± 96.23 | 230.00 ± 68.13 | 0.29 |
Values in mean ± standard deviation or frequency
BMI body mass index, HR heart rate, RR respiratory rate, SBP systolic blood pressure, DBP diastolic blood pressure
*p < 0.05
Physical activity level between the groups
| Physical activity level | Active ( | Sedentary ( | |
|---|---|---|---|
| IPAQ (min.week−1) | 403.57 ± 521.36 | 27.80 ± 43.06 | < 0.001* |
| MET (min.week−1) | 1441.18 ± 1815.84 | 96.42 ± 148.53 | < 0.001* |
Values in mean ± standard deviation
*p < 0.05
Primary outcomes
| Outcomes | Active ( | Sedentary ( | |
|---|---|---|---|
| Onset of symptom until admission (days) | 9.21 ± 3.53 | 9.61 ± 3.00 | 0.72 |
| Length of stay (days) | 6.50 ± 3.46 | 11.48 ± 7.63 | 0.03* |
| Disease duration (days) | 15.71 ± 4.84 | 21.09 ± 7.69 | 0.02* |
Values in mean ± standard deviation
*p < 0.05
Secondary outcomes
| Outcomes | Active ( | Sedentary ( | |
|---|---|---|---|
| Needed to ICU (%) | 1 (7.14) | 9 (36.00) | 0.06 |
| Dexamethasone (%) | 14 (100.00) | 25 (100.00) | 1 |
| Azithromycin (%) | 5 (35.71) | 6 (24.00) | 0.43 |
| CT-abnormalities# | |||
| Mild (%) | 7 (58.33) | 3 (12.00) | 0.01* |
| Moderate (%) | 2 (16.67) | 13 (52.00) | |
| Accentuated (%) | 3 (25.00) | 9 (36.00) | |
Values in absolute and relative frequency
ICU intensive care unit, CT computed tomography
*p < 0.05
#12 patients in active group were submitted to CT